Cantargia AB (CHIX:CANTAS) Beta: 0.5240 (As of Jun. 27, 2026)


CHIX:CANTAS Cantargia AB CHIX:CANTAS
37 GF Score
Price kr4.17
! 2 Warning Signs
View Full Analysis

What is Cantargia AB Beta?

Cantargia AB CHIX:CANTAS 37 Beta is 0.5240 as of Jun. 27, 2026. GuruFocus rates CHIX:CANTAS with a GF Score™ of 37/100. The stock has 2 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-27), Cantargia AB's Beta is 0.5240.


Cantargia AB  (CHIX:CANTAs) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Cantargia AB Beta Related Terms


Cantargia AB Beta Historical Data

* Premium members only.

The historical data trend for Cantargia AB's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cantargia AB Beta Chart

Cantargia AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 4.01 4.11 3.26

Cantargia AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.70 2.90 2.89 3.26 0.42

CHIX:CANTAS vs VRTX, REGN, ALNY: Beta Comparison

For the Biotechnology subindustry, Cantargia AB's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cantargia AB Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cantargia AB's Beta distribution charts can be found below:

* The bar in red indicates where Cantargia AB's Beta falls into.


CHIX:CANTAS
37GF Score
Cantargia AB CHIX:CANTAS
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cantargia AB Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.5240 mean?
Cantargia AB (CHIX:CANTAS) has a Beta of 0.5240 as of Jun. 27, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Cantargia AB and its competitors.
Is Cantargia AB's Beta too high?
Cantargia AB's current Beta is 0.5240. Overall, Cantargia AB has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Cantargia AB's Beta compare to VRTX and REGN?
Cantargia AB's Beta of 0.5240 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Cantargia AB and its competitors. Cantargia AB's current Beta is 0.5240. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cantargia AB stock overvalued right now?
Cantargia AB (CHIX:CANTAS) has a current Beta of 0.5240. The current Beta is 0.5240. Cantargia AB's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Cantargia AB (CHIX:CANTAS), the current Beta is 0.5240 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cantargia AB Business Description

Other Exchanges CANTA:Sweden7V3:Germany
Address Scheelevagen 27, Lund, SWE, 223 63
Cantargia AB is a Swedish biotech company that develops targeted antibody-based drugs for cancer as well as autoimmune and inflammatory diseases. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's development programme includes the candidate drugs nadunolimab (CAN04) and CAN10, both in the clinical development stage, which were latter acquired by Otsuka Pharmaceutical in 2025. In addition, the company is also developing a a pre-clinical project CAN14, derived from antibody platform CANxx. Geographically, the company's revenues have been generated in the markets of Japan and United States.
37GF Score

Get the complete analysis for CHIX:CANTAS

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr4.17
Price